Logo image of OCX

ONCOCYTE CORP (OCX) Stock Price, Quote, News and Overview

NASDAQ:OCX - Nasdaq - US68235C2061 - Common Stock - Currency: USD

3.1  +0.02 (+0.65%)

OCX Quote, Performance and Key Statistics

ONCOCYTE CORP

NASDAQ:OCX (5/1/2025, 9:22:34 PM)

3.1

+0.02 (+0.65%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.75
52 Week Low1.92
Market Cap88.66M
Shares28.60M
Float22.30M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13/bmo
IPO12-30 2015-12-30


OCX short term performance overview.The bars show the price performance of OCX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30 40

OCX long term performance overview.The bars show the price performance of OCX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60 -80

The current stock price of OCX is 3.1 USD. In the past month the price increased by 5.08%. In the past year, price increased by 16.54%.

ONCOCYTE CORP / OCX Daily stock chart

OCX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.83 342.01B
AMGN AMGEN INC 14.32 152.57B
GILD GILEAD SCIENCES INC 13.34 128.71B
VRTX VERTEX PHARMACEUTICALS INC 1720.21 128.25B
REGN REGENERON PHARMACEUTICALS 13.32 64.50B
ARGX ARGENX SE - ADR 336.79 39.07B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.19B
ONC BEIGENE LTD-ADR N/A 27.55B
BNTX BIONTECH SE-ADR N/A 24.62B
NTRA NATERA INC N/A 20.46B
SMMT SUMMIT THERAPEUTICS INC N/A 18.19B
BIIB BIOGEN INC 7.34 17.70B

About OCX

Company Profile

OCX logo image OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 46 full-time employees. The company went IPO on 2015-12-30. The firm is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.

Company Info

ONCOCYTE CORP

15 Cushing

Irvine CALIFORNIA 92618 US

CEO: Ronald Andrews

Employees: 45

Company Website: https://oncocyte.com/

Investor Relations: https://investors.oncocyte.com/

Phone: 19494097600

ONCOCYTE CORP / OCX FAQ

What is the stock price of ONCOCYTE CORP today?

The current stock price of OCX is 3.1 USD. The price increased by 0.65% in the last trading session.


What is the ticker symbol for ONCOCYTE CORP stock?

The exchange symbol of ONCOCYTE CORP is OCX and it is listed on the Nasdaq exchange.


On which exchange is OCX stock listed?

OCX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ONCOCYTE CORP stock?

8 analysts have analysed OCX and the average price target is 4.51 USD. This implies a price increase of 45.32% is expected in the next year compared to the current price of 3.1. Check the ONCOCYTE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ONCOCYTE CORP worth?

ONCOCYTE CORP (OCX) has a market capitalization of 88.66M USD. This makes OCX a Micro Cap stock.


How many employees does ONCOCYTE CORP have?

ONCOCYTE CORP (OCX) currently has 45 employees.


What are the support and resistance levels for ONCOCYTE CORP (OCX) stock?

ONCOCYTE CORP (OCX) has a support level at 2.87 and a resistance level at 3.35. Check the full technical report for a detailed analysis of OCX support and resistance levels.


Is ONCOCYTE CORP (OCX) expected to grow?

The Revenue of ONCOCYTE CORP (OCX) is expected to grow by 104.75% in the next year. Check the estimates tab for more information on the OCX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ONCOCYTE CORP (OCX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ONCOCYTE CORP (OCX) stock pay dividends?

OCX does not pay a dividend.


When does ONCOCYTE CORP (OCX) report earnings?

ONCOCYTE CORP (OCX) will report earnings on 2025-05-13, before the market open.


What is the Price/Earnings (PE) ratio of ONCOCYTE CORP (OCX)?

ONCOCYTE CORP (OCX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.4).


What is the Short Interest ratio of ONCOCYTE CORP (OCX) stock?

The outstanding short interest for ONCOCYTE CORP (OCX) is 1.81% of its float. Check the ownership tab for more information on the OCX short interest.


OCX Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to OCX. When comparing the yearly performance of all stocks, OCX is one of the better performing stocks in the market, outperforming 94.85% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

OCX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to OCX. OCX may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OCX Financial Highlights

Over the last trailing twelve months OCX reported a non-GAAP Earnings per Share(EPS) of -4.4. The EPS decreased by -22.22% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -173.67%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%8.96%
Sales Q2Q%373.25%
EPS 1Y (TTM)-22.22%
Revenue 1Y (TTM)25.07%

OCX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to OCX. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of 75.47% and a revenue growth 104.75% for OCX


Ownership
Inst Owners66.6%
Ins Owners1.25%
Short Float %1.81%
Short Ratio5.14
Analysts
Analysts75
Price Target4.51 (45.48%)
EPS Next Y75.47%
Revenue Next Year104.75%